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Abstract
Background: Gliomas represent the most common primary malignant brain tumors, yet little is known about the
molecular pathogenesis of these tumors. The highly-regulated Wnt signal transduction pathway is essential for
normal developmental processes, and defects in the pathway are closely linked to oncogenesis. Dickkopf-1 (DKK-1)
is a secreted protein that acts as a potent inhibitor of the Wnt pathway. The aim of this study was to examine the
expression profile of DKK-1 gene in human glioma and its association with tumor malignancy.
Methods: We determined the expression levels of DKK-1 transcript and protein in 12 glioblastoma cell lines,
medulloblastoma cells, low-grade glioma cells, and human astrocyte cells by semiquantitative RT-PCR and ELISA. A
total of 47 tumor biopsy specimens and 11 normal brain tissue samples from patients with cerebral trauma internal
decompression were embedded in paraffin blocks and used for immunostaining. Twenty-six primary tumors and 7
corresponding brain samples were stored in liquid nitrogen and used for RT-PCR. We further examined serologic
concentrations and cerebral fluid levels of DKK-1 in patients with tumors.
Results: DKK-1 could only be detected in 12 human glioblastoma cell lines, not in a panel of other tumor and
normal cell lines. The difference between glioma patients and healthy individuals was significant. Kendall’s tau-c
association analysis also revealed the increased DKK-1 protein expression in tumor tissues of higher pathologic
classification. The levels of cerebral fluid DKK-1 protein were significantly higher in glioma patients than in healthy
donors or in neuronal benign tumor patients, suggesting that the DKK-1 molecule in cerebral fluids can be
applicable to detect the presence of glioma and be developed as a novel prognostic treatment.
Conclusion: The Wnt antagonist DKK-1 gene may have important roles in glioma tumorigenesis and act as a novel
biomarker in human malignant glioblastoma.
Background
The Wnt signaling cascade plays a critical role in cell
patterning, proliferation, and fate-determination during
embryogenesis, In humans, the Wnt glycoproteins com-
prise a family of extracellular ligands that regulate
homeostasis and development by binding to Frizzled
(Fz) receptors and the LDL receptor-related protein 5/6
(LRP5/6) located at the plasma membrane [1]. Wnt gly-
coproteins signal through canonical and noncanonical
pathways. The canonical Wnt pathway involves the
stabilization and accumulation of b-catenin in the cyto-
plasm, its subsequent nuclear translocation and gene
regulation. Accumulation of b-catenin in the cytosol is
caused through inhibition of its proteasome-targeting
phosphorylation by glycogen synthase kinase-3, which
forms a complex with the tumor suppressor adenoma-
tous polyposis coli (APC) and Axin proteins. And in the
nucleus, b-catenin associates with T-cell factor/lympho-
cyte enhancer factor (TCF/LEF) family of transcription
factors to stimulate the expression of multiple Wnt tar-
get genes including c-myc, c-jun, and cyclin D1 [2,3].
Defects in this highly regulated signal transduction path-
way have been closely linked to oncogenesis, i.e. early
activation by mutation in APC or b-catenin occurs in a
proportion of carcinomas [2,4]. It is also thought that an
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important component of cancer induction and progres-
sion may be the loss of control over b-catenin levels [5].
Unlike the canonical Wnt pathway, non-canonical path-
ways transduce signals independent of b-catenin and
include the Wnt/Ca2+ pathway, the planar cell polarity
(PCP) pathway in Drosophila, the convergent extension
pathway in vertebrates, and the JNK pathway, a poten-
tial mediator of noncanonical signaling with unclear
roles [6]. Noncanonical pathways lead to the activation
of the small GTPases Rho and Rac, or kinases such as
JNK and PKC, or to modulation of Ca2+ levels [4,7].
Wnt signals are extracellularly regulated by several
natural antagonists that can be classified into two broad
groups of molecules, both of which prevent Wnt-Fz
interaction at the cell surface [8]. The first group con-
sists of proteins that bind directly to the Wnt ligand
and include Wnt inhibitory factor (WIF-1), the secreted
frizzled-related protein (sFRP) family, and Cerberus. The
second group includes members of the DKK family,
secreted glycoproteins which inhibit the Wnt pathway in
a manner distinct from the other Wnt antagonists and
do not prevent Wnt from associating with Fz receptors
[8,9]. Previous results have demonstrated that Wnt must
bind to both LRP5/6 and Fz in order to form a func-
tional ligand-receptor complex that activates the cano-
nical Wnt/b-catenin pathway [9]. DKK-1, the most
well-characterized member of the latter group of
antagonists, blocks Wnt signaling by binding to LRP5/6
co-receptor and the membrane-anchored molecule, Kre-
men, thereby inducing LRP endocytosis that inhibits the
Wnt-induced Fz-LRP5/6 complex formation and triggers
the consequent removal of the DKK-1-LRP5/6 complex
from the plasma membrane during mid blastula transi-
tion [2,10-13].
It is thought that the antagonistic effect of DKK-1 is spe-
cific for the canonical Wnt/b-catenin signaling pathway
[11,14]. However, one recent report has demonstrated that
restoration of DKK-1 expression suppresses cell growth
and induces apoptotic cell death in b-catenin-deficient
mesothelioma cell lines H28 and MS-1. Moreover, a
small-molecule inhibitor of JNK inhibited the apoptosis
induced by DKK-1 overexpression in these cells. Similarly,
DKK-1 sensitized HeLa cervical carcinoma cells to apopto-
sis, acting as a suppressor of cell transformation. This
effect of DKK-1 was not due to inhibition of b-catenin/
TCF4-regulated transcription, as the cellular localization
of b-catenin and activities of targets in the Wnt/b-catenin
pathway remained unchanged [15]. These data suggest
that DKK-1 may be able to antagonize Wnt signaling
and have additional tumor suppressive effects through
b-catenin-independent non-canonical pathways (i.e., the
Wnt/JNK pathway).
Glioma is one of the most lethal malignancies of the
human brain and is the leading cause of cancer-related
death in the world. Despite some advances in early
detection, most of the patients are at advanced stages at
the time of diagnosis, and the prognosis of them still
remains poor. In spite of the use of modern surgical
techniques combined with various treatment modalities,
such as radiotherapy and chemotherapy, the overall
5-year survival rate of glioma still remains at ~20%.
Although several tumor markers are elevated in serum
of glioma patients, no tumor marker has been suffi-
ciently useful for detection of glioma at potentially cura-
tive stage, and a limited number of practical prognostic
biomarker are presently available for selection of treat-
ment modalities for individual patients.
Nowadays, the interaction of genes and environment
is widely investigated by a combination of the molecular
biology, cell biology, and genetic approach. It has been
demonstrated that the progression and development of
glioma is closely-related with the overexpression of sev-
eral oncogenes and inactivation of tumor suppressor
genes, however, the specific molecular mechanism
remains largely unknown. Thus, the identification of
putative genes and characterization of the relationship
between changes of gene functions and progression of
glioma in different stages are urgently need for isolating
potential molecular targets for diagnosis, treatment,
and/or prevention of glioma. In the current study, we
analyzed the expression of DKK-1, an antagonist of Wnt
signaling, in clinical glioma materials and cell lines at
the mRNA and protein level. We also detected its
expression in serum and cerebrospinal fluid of glioma
patients.
Materials and methods
Cell lines, patients, and tumors
The 14 cancer cell lines used in this study included
twelve glioblastomas (U251, SF767, SF295, T98G,
MGR1, MGR2, MGR3, SKMG-1, SKMG-4, UWR7,
UW-28, and SKI-N2), one medulloblastoma (D341), and
one low-grade glioma (SHG-44). All cells were grown in
monolayer in appropriate medium supplemented with
15% fetal calf serum (Hyclone, Logan, UT) and cultured
at 37°C in a humid incubator with 5% CO2. Human
astrocyte cells were used as a normal control.
A total of 47 paraffin-embedded primary tumors and
11 normal brain tissue (internal decompression in cere-
bral trauma) samples and used for semiquantitative
reverse transcription-PCR and immunostaining had
been obtained from 58 patients (30 female and 28 male
patients; median age of 45.5 with a range of 11 to 74
years) undergoing curative surgery at the First Affiliated
Hospital of Soochow University (Suzhou, China). A total
of 26 tumor biopsy specimens and 7 corresponding nor-
mal brain tissue samples stored in liquid nitrogen
(14 female and 19 male patients; median age of 47.4
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with a range of 13 to 79 years) had also been obtained
earlier from patients undergoing curative surgery at the
First Affiliated Hospital of Soochow University (Suzhou,
China) with informed consent. Clinical stage was judged
according to the 2007 WHO classification of tumors of
the central nervous system [16]. The use of all clinical
materials in this study was approved by individual insti-
tutional Ethical Committees.
Serum and cerebrospinal fluid samples
Serum samples were obtained with written informed
consent from 8 healthy individuals and from 12 spongio-
blastomas, 6 low-grade gliomas, and 20 benign tumor
patients in their neuronal system, i.e. the pituitary tumor,
meningioma, nerve sheath tumor, and acoustic nerve
tumor. The median age of these samples (20 males and
26 females) was 50.1 with a range of 26 to 79 years. Cere-
bral fluid samples from a total of 36 cancer patients and
6 healthy control individuals were also selected with
informed consent from 26 males and 16 females (median
age of 48.9 with a range of 26 to 79 years). These 36
cancer cases included 14 spongioblastomas, 11 low-grade
gliomas, and 11 patients with benign tumor in the neuro-
nal system (pituitary tumor, meningioma, nerve sheath
tumor, acoustic nerve tumor, etc.). The serum and cere-
brospinal fluid samples in this study were obtained at the
time of diagnosis, centrifuged, and the supernatants were
stored in liquid nitrogen.
RNA preparation and cDNA synthesis
Total cellular RNAs from cell lines and tissues were
extracted and purified by using the Trizol reagent (Invi-
trogen, Inc.) according to the protocol of the supplier.
Before RNA extraction, individual tissue samples were
preexamined by frozen section histologic examination to
document the histopathologic appearance of the speci-
men. About 10 μg total RNA from each sample was
reversely transcribed to single-stranded cDNAs using
random hexamers (Shanghai Sangon, Inc.) as primer
and M-MLV reverse transcriptase (Promega, Inc.).
Semiquantitative RT-PCR analysis of hDKK-1 expression
Analysis of the hDKK-1 mRNA expression was per-
formed by a semiquantitative RT-PCR assay on Perkin
Elmer PCR system 9600 using synthesized hDKK-1-
specific primers together with primers for the house-
keeping gene GAPDH as an internal control to ensure
RNA quality and loading accuracy. Primer sequences
were as follows: DKK-1, 5’-TCACGCTATGTGCTG
CCCCG-3’ and 5’-TGAGGCACAGTCTGATGACCG
GA-3’, product size 223 bp; and GAPDH, 5’-AGAAGGC
TGGGGCTC ATTTG-3’ and 5’-AGGGGCCATCCA-
CAGTCTTC-3’, product size 258 bp. PCRs were opti-
mized for the number of cycles to ensure product
intensity to be within the linear phase of amplification.
The PCR protocol consisted of an initial denaturation
step of 95°C for 7 minutes, followed by 32 cycles of a
three-step program of 94°C for 30 seconds, 56°C for
30 seconds, and 72°C for 45 seconds, and a final exten-
sion step of 72°C for 7 minutes. The PCR was performed
in a final volume of 25 μl in the presence of 2.0 mM
MgCl2, 0.75 U of Taq polymerase in PCR buffer, and
5 pmol of the hDKK-1 and GAPDH primers. PCR pro-
ducts were separated and analyzed on 1.5% agarose gels.
Elisa
Levels of DKK-1 in cell medium, cell lysate, serum, and
cerebral fluid were measured by ELISA with a commer-
cially available enzyme test kit (R&D Systems, Inc.) accord-
ing to the supplier’s recommendations. First, a rabbit
polyclonal antibody specific to DKK-1 was added to a
96-well microplate as a capture antibody and incubated
overnight at room temperature. After washing away any
unbound antibody, 0.75% BSA was added to the wells and
incubated for at least 1 h at room temperature for blocking.
After a wash, 3-fold diluted sera were added to the wells
and incubated for 2 h at room temperature. After washing
away any unbound substances, a biotinylated polyclonal
antibody specific for DKK-1 was added to the wells as a
detection antibody and incubated for 2 h at room tempera-
ture. After a wash to remove any unbound antibody-
enzyme reagent, horseradish peroxidase (HRP)-streptavidin
was added to the wells and incubated for 20 min. After a
wash, a substrate solution was added to the wells and
allowed to react for 20 min. The reaction was stopped by
adding 50 μL of 2 N sulfuric acid. Color intensity was
determined by a photometer at a wavelength of 490 nm,
with a reference wavelength of 570 nm. Differences in the
levels of DKK-1 between different groups were analyzed by
t test. Significance was defined as P < 0.05.
Immunohistochemistry
To investigate the DKK-1 protein in clinical samples that
had been embedded in paraffin blocks, we stained the
sections as previously described [17]. Briefly, 3.3 μg/mL
of a rabbit polyclonal anti-hDKK-1 antibody (Santa Cruz
Biotechnology) were added to each slide after blocking of
endogenous peroxidase and proteins, and the sections
were incubated with biotin-labeled anti-rabbit IgG as the
secondary antibody. Substrate-diaminobezidine (DAB)
was added, and the specimens were counterstained with
hematoxylin.
Statistical analysis
Statistical analyses were done using the SAS6.12 statisti-
cal program. Kendall’s tau-c association analysis was
applied between DKK-1 expression and pathologic
tumor classification. We also analyzed positive DKK-1
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expression rate in glioblastoma and normal brain tissues
by chi-square test. Significance was defined as P < 0.05.
Results
Differential expression of DKK-1 mRNA and protein in
various cell lines
We first sought to identify the differential expression of
the DKK-1 gene in 12 glioblastoma cell lines, medulloblas-
toma cells, low-grade glioma cells, and human astrocytes
as a control using semi-quantitative RT-PCR analysis
(Figure 1). In glioblastoma cell lines UW-28, SKI-N2, and
SF295, DKK-1 mRNA expression was relatively lower as
compared with other glioblastoma cells. Concentration of
DKK-1 protein was also determined by ELISA in culture
medium and cell lysate of these 14 cell lines (Table 1).
U251 cells have the highest levels of DKK-1 expression in
both of the culture medium and cell lysate, while glioblas-
toma cell lines SKMG-4 and UW-28 have the lowest
DKK-1 levels in the culture medium and cell lysate,
respectively. Following normalization and statistical analy-
sis of fluorescence intensity data by t test, we identified
that the difference of DKK-1 protein expression was sig-
nificant between the culture medium and cell lysate in 12
glioblastoma cell lines (p < 0.05), consistent with the fact
that DKK-1 was a secreted peptide shown previously to
influence cell growth, differentiation and apoptosis by
inhibiting Wnt signaling [18]. It should also be noted that
the very low expression level of DKK-1 mRNA was not in
concordance with the higher level of its protein in SKI-N2
cells. Expression of DKK-1 mRNA and protein was unde-
tectable in medulloblastoma cells, low-grade glioma cells,
and human astrocytes. Thus, DKK-1 can serve as a marker
for diagnosis of glioma through detecting the expression of
the protein and mRNA of DKK-1.
DKK-1 expression in tumors and normal tissues
To identify the association of DKK-1 expression with
pathologic tumor classification, we did DKK-1 expression
profile analysis in patients at various clinical stages of
glioma and in healthy controls. We screened 58 tissue
samples embedded in paraffin blocks by immunohisto-
chemistry and identified expression of DKK-1 protein
located at cytoplasm (with granular appearance) of the
great majority of the glioma samples examined (Table 2).
The proportion of the DKK-1-positive cases was 91.5%
for glioma (43 of 47). Representative data are shown in
Figure 2. The difference between glioma patients and
healthy individuals was significant (p < 0.05). Kendall’s
tau-c association analysis also revealed the increased
DKK-1 protein expression in tumor tissues of higher
pathologic classification (rτ = 0.3178, P < 0.01) (Table 3).
The relatively high false-positive rate here (2 of 11) may
be eliminated by testing more normal volunteers or mea-
suring more tumor markers to improve overall sensitivity
for detection of glioblastoma. We subsequently con-
firmed by means of semiquantitative RT-PCR experiment
overexpression of DKK-1 mRNA in 26 tumor tissues
Figure 1 Expression of DKK-1 mRNA in glioblastoma cell lines
was higher than that in control by using semi-quantitative
RT-PCR.
Table 1 Levels of DKK-1 expression were detected in the
culture medium and cell lysate of all 14 cancer cell lines
by ELISA
Cancer cell lines and control Concentration of DKK1 (pg/ml)
Normal cells
Human astrocytes 0 0

















* and ** indicate the respective concentration of DKK-1 protein tested in the
culture medium and cell lysate.
Table 2 DKK1-1 expression in glioma and corresponding
normal brain tissues
DKK-1expression
Strong (++) Weak (+) Negative (-) Total
Glioblastoma tissue 28 15 4 47
Normal brain tissue 0 2 9 11
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frozen in liquid nitrogen, but its transcript was
hardly detectable in any other normal tissues (P < 0.05)
(Figure 3). These observations demonstrated that DKK-1
was a novel molecule that can be applicable to detect
presence of glioma at an early stage and thus help us
develop novel treatments based on the biological charac-
teristics of tumor cells.
Serologic concentrations and cerebral fluid levels of DKK-
1 in patients with tumors
Because DKK-1 encodes a secreted protein, we investi-
gated the DKK-1 protein secreted into sera of patients
with glioma or neuronal benign tumor and healthy indivi-
duals. ELISA experiments detected DKK-1 protein in sero-
logic samples from 18 patients with spongbioblastoma or
low-grade glioma, 20 benign tumor patients in their neu-
ronal system, and 8 healthy controls. Unexpectedly, differ-
ences were not significant between glioma patients and
healthy individuals/neuronal benign tumor patients, and
between neuronal benign tumor patients and healthy con-
trols (Figure 4A), suggesting that more clinical specimens
should be examined. Although previous results support
the high specificity and the great potentiality of serum
DKK-1 as a biomarker for detection of myeloma/lung and
esophageal carcinomas at an early stage and for monitor-
ing of the relapse of the disease [17,19]. in patients with
Figure 2 Different hDKK-1 expression levels in tumor and
healthy brain tissues analyzed by immunohistochemistry.
Table 3 Correlation between DKK-1 expression in
different tumor stages and pathologic tumor
classification
Stage DKK-1expression
Strong (++) Weak (+) Negative (-) Total
I 1 2 2 5
II 10 9 1 20
III 13 3 1 17
IV 4 1 0 5




Figure 4 DKK-1 concentration in sera (A) and cerebral fluid (B)
samples determined by ELISA in patients with tumors and in
healthy controls. *, difference between the glioma group and
neuronal benign tumor group. **, difference between the glioma
group and normal control group. ***, difference between the
neuronal benign tumor group and healthy control group. The
DKK-1 concentration in cerebral fluid is increased in glioma, and
differences may exist among different glioma grades, suggesting
the role of DKK-1 in glioma pathogenesis.
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multiple glioma, serum concentrations of DKK-1 protein
were close to the limit of detection by ELISA analysis due
to the blood-brain barrier. It is also possible that certain
substances with similar DKK-1 protein structure exist in
sera and thus increase the background signal in ELISA
experiments and reduce the expression differences
between each group.
To evaluate the clinical usefulness of cerebral flucid
DKK-1 level as a tumor detection biomarker, we also
measured by ELISA the levels of DKK-1 protein in cere-
bral flucid samples from the same set of tumor patients
and control individuals. The levels of cerebral fluid DKK-
1 protein were significantly higher in glioma patients
than in healthy donors or in neuronal benign tumor
patients (P < 0.05); the difference between healthy indivi-
duals and neuronal benign tumor patients was not signif-
icant (Figure 4B), suggesting that the DKK-1 molecule
secreted and stably expressed in cerebral fluids can also
be applicable to detect presence of glioblastoma and to
develop novel prognostic treatments.
Discussion
Human DKK-1 is a member of the DKK gene family
and maps to chromosome 10q11.2 [20]. DKK-1 is
expressed in a timely and spatially controlled manner
during development. It was first isolated in Xenopus,
where it is expressed in the Spemann organizer as a
head inducer [21], and its important role in normal
head development in mice has also been identified [22].
Other members of the family are DKK-2, DKK-3, and
DKK-4, which all contain two cysteine-rich domains
that are highly conserved among different family mem-
bers [18]. Although DKK-1 functions as an inhibitor of
the Wnt signaling pathway [21], DKK-2 activates Wnt
signaling in Xenopus embryos [23].
DKK-1 has multiple biological roles in a variety of can-
cers. The forced expression of DKK-1 in the small intes-
tine inhibits cell proliferation and the generation of
secretory lineages [24,25]. Furthermore, DKK-1 seems to
induce the proliferation of human adult bone marrow
stem cells [26] and contribute to the control of osteoporo-
sis, as mutations in LRP5 that impede binding of DKK-1
are responsible for high bone density [27]. DKK-1 also
inhibits osteoblastic differentiation and high circulating
levels of DKK-1 in patients with multiple myeloma are
associated with osteolytic lesions [28]. Gene expression
profile analysis of lung and esophageal carcinomas
revealed that DKK-1 was highly transactivated in the great
majority of lung cancers and esophageal squamous cell
carcinomas [17]. Overexpression of DKK-1 has also been
detected in human hepatoblastomas and Wilms’ tumors
[29]. In contrast, expression of the DKK-1 gene, a down-
stream target of b-catenin/TCF, decreases in human colon
tumors, indicating its tumor suppressing role in this
neoplasia [1]. Recent evidence also suggests that DKK-1 is
a functional suppressor of HeLa cell transformation [15].
Human DKK-1 was reported to be responsive to p53
[30], although it has been shown to be induced by DNA
damage and to sensitize to apoptosis in a p53-independent
manner [31]. Recently, glucocorticoids have been reported
to enhance DKK-1 expression in human osteoblasts [32].
However, little is known about the control mechanism of
DKK-1 expression in human gliomas.
Medulloblastoma is a heterogeneous pediatric brain
tumor, and DKK-1 expression in primary medulloblas-
toma cells and patient samples by RT-PCR was found to
be significantly down-regulated relative to normal cere-
bellum [33]. Transfection of a DKK-1 gene construct
into D283 cell lines suppressed medulloblastoma tumor
growth in colony focus assays by 60% (P < 0.001), and
adenoviral vector-mediated expression of DKK-1 in
medulloblastoma cells increased apoptosis fourfold (P <
0.001) [33]. In the present study, we observed that
DKK-1 transcript and protein widely express in glioma
cell lines and pathologic tumor tissues with increased
levels but not in medulloblastoma cell line D341, indi-
cating different expression pattern of DKK-1 in intracra-
nial neuroepithelial carcinomas.
Although secreted Wnt antagonists have been found
to be down-regulated or silenced in certain carcinomas
[34-38], DKK-1 expression is restored in glioma cells.
Our data suggest the possible roles of DKK-1- in carci-
nogenesis of gliomas. It remains unclear if the increased
DKK-1 expression is in response to Wnt activation in
gliomas or independent effect. Further detailed experi-
ments will shed light on this interesting point.
Conclusion
In this paper we report that the role of DKK-1, an inhi-
bitor of the Wnt pathway, in gliomas. We demonstrate
that DKK-1 is expressed by malignant glioma cells but
not by other tumor cell lines investigated using RT-PCR
and ELISA. Our findings are confirmed by immunohis-
tochemical stainings of DKK-1 in glioma and normal
human brain tissue. Elevated DKK-1 levels are also
found in cerebrospinal fluid of glioma patients. Thus,
we conclude that DKK-1 may have an important role in
glioma tumorigenesis.
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